Therefore, this trial concluded that the combination of bevacizumab and atezolizumab did not meet the predefined efficacy endpoint, as the addition of bevacizumab to PD-L1 blockade did not appear to enhance the ORR in cervical cancer. Here, CD274 is linked to cervical cancer.